Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 3/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.39 |
| ▸ | INSR | P06213 | 2/20 | 0.39 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22985906 | 0.84 | ALK (0.46) | EGFRIGF1RALKINSR | |
| SCHEMBL23010799 | 0.83 | EGFR (0.49) | EGFRTNK2IGF1RZAP70ALK | |
| SCHEMBL22985876 | 0.82 | FES (0.49) | EGFRTNK2IGF1RZAP70ALK | |
| SCHEMBL21183052 | 0.76 | ALK (0.55) | EGFRIGF1RALKINSR | |
| SCHEMBL3954476 | 0.76 | ALK (0.57) | EGFRTNK2IGF1RZAP70ALK | |
| SCHEMBL18018797 | 0.70 | ALK (0.56) | EGFRTNK2IGF1RZAP70ALK | |
| SCHEMBL4056958 | 0.69 | FES (0.68) | EGFRTNK2IGF1RZAP70ALK | |
| SCHEMBL12429275 | 0.68 | IGF1R (0.71) | IGF1R | |
| SCHEMBL12429336 | 0.67 | PTK2 (0.65) | IGF1R | |
| SCHEMBL12245802 | 0.67 | ALK (0.63) | EGFRIGF1RALKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |